{"url_path":"/sec/cik-0001567892/8-k/2026-06-03/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1567892/0001104659-26-069792-index.html","accession_number":"0001104659-26-069792","cik":"0001567892","ticker":null,"issuer_name":"Keenova Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1567892/0001104659-26-069792-index.html","primary_entity_key":"0001567892","primary_entity_name":"Keenova Therapeutics plc"},"word_count":459,"has_tables":true,"body_markdown":"**Item 5.07.**\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nEach of the items listed below\nwas submitted to a vote of shareholders at the 2026 Annual General Meeting of Shareholders (the “2026 AGM”) on June 2, 2026\nand is described in more detail in Keenova Therapeutics plc’s (the “Company”) definitive proxy statement for the 2026\nAGM, filed by the Company with the U.S. Securities and Exchange Commission on April 27, 2026. The final results for each of the matters\nsubmitted to a vote of shareholders are as follows:\n\n \n\n**Proposal 1:**By separate\nresolutions, to elect as directors and to hold office, expiring at the end of the Company’s Annual General Meeting of Shareholders\nin 2027 (the “2027 AGM”), the following individuals:\n\n \n\n \n \nFOR\n \n \nAGAINST\n \n \nABSTAIN\n \n \n**BROKER**\n\n**NON-VOTES**\n \n\nPaul M. Bisaro\n \n25,282,713\n \n \n8,884\n \n \n191,295\n \n \n310,829\n \n\nLeslie Donato\n \n25,291,597\n \n \n0\n \n \n191,295\n \n \n310,829\n \n\nKatina Dorton\n \n25,291,597\n \n \n0\n \n \n191,295\n \n \n310,829\n \n\nPaul Efron\n \n25,162,447\n \n \n84,006\n \n \n236,439\n \n \n310,829\n \n\nScott Hirsch\n \n25,176,548\n \n \n72,773\n \n \n233,571\n \n \n310,829\n \n\nSophia Langlois\n \n25,265,940\n \n \n25,657\n \n \n191,295\n \n \n310,829\n \n\nSigurdur O. Olafsson\n \n25,285,209\n \n \n6,388\n \n \n191,295\n \n \n310,829\n \n\nMarc Yoskowitz\n \n25,272,285\n \n \n19,312\n \n \n191,295\n \n \n310,829\n \n\nJonathan Zinman\n \n25,265,940\n \n \n25,657\n \n \n191,295\n \n \n310,829\n \n\n \n\nEach of the foregoing nominees\nwas elected to hold office until the conclusion of the 2027 AGM or until his or her earlier death, resignation or removal.\n\n \n\n**Proposal 2:**Advisory non-binding\nvote to approve the re-appointment of PricewaterhouseCoopers LLP as the independent auditors of the Company and, by binding vote, to authorize\nthe Audit Committee of the Board of Directors to set the independent auditors’ remuneration.\n\n \n\nFOR\n \n \nAGAINST\n \n \nABSTAIN\n \n \n**BROKER** **NON-VOTES**\n \n\n25,602,426\n \n \n0\n \n \n191,295\n \n \n0\n \n\n \n\n**Proposal 3:**Advisory non-binding\nvote to approve the Company’s executive compensation.\n\n \n\nFOR\n \n \nAGAINST\n \n \nABSTAIN\n \n \n**BROKER** **NON-VOTES**\n \n\n24,965,301\n \n \n326,296\n \n \n191,295\n \n \n310,829\n \n\n \n\n**Proposal 4:**Advisory non-binding\nvote to approve the frequency of future advisory non-binding votes to approve the Company’s executive compensation.\n\n \n\n1 YEAR\n \n \n2 YEARS\n \n \n3 YEARS\n \n \nABSTAIN\n \n \n**BROKER** **NON-VOTES**\n \n\n25,117,919\n \n \n172,952\n \n \n726\n \n \n191,295\n \n \n310,829\n \n\n \n\nIn light of the results of Proposal\n4, and consistent with the Board of Directors’ recommendation, the Company intends to continue to include an advisory non-binding\nvote to approve the Company’s executive compensation in its proxy materials annually until the next required vote on the frequency\nof future advisory non-binding votes to approve the Company’s executive compensation.\n\n \n\n**Proposal 5:**Approve the\nreduction of Company capital (Special Resolution).\n\n \n\nFOR\n \n \nAGAINST\n \n \nABSTAIN\n \n \n**BROKER** **NON-VOTES**\n \n\n25,256,218\n \n \n35,379\n \n \n191,295\n \n \n310,829\n \n\n \n\n**Proposal 6:**Approve an\namendment to the Company’s articles of association (Special Resolution).\n\n \n\nFOR\n \n \nAGAINST\n \n \nABSTAIN\n \n \n**BROKER** **NON-VOTES**\n \n\n25,476,547\n \n \n6,345\n \n \n0\n \n \n310,829\n \n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**KEENOVA THERAPEUTICS PLC**\n\n \n(registrant)\n\n \n \n \n\n \nBy:\n/s/ Mark Tyndall\n\n \n \nMark Tyndall\n\n \n \n*Executive Vice President, Chief Legal Officer &\nCorporate Secretary*\n\n \n\nDate: June 3, 2026"}